ReviewJournal of personalized medicine2026

Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors.

Ilaria Poli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.